This week’s Lattice Brief asks where 3D printing actually makes money: the listed printer makers lose money, while treatments with printing inside, medical software, consumables ecosystems and clinically priced devices earn the margins. Also inside: FDA clears a 3D printed porous titanium cervical system, an ARPA-H liver bioprinting award, robotic bioprinting for diabetic wounds, and the VDMA autumn survey. The Lattice Brief returns the week of November 2.

The big thing

Where 3D printing actually makes money

The industry feels better. VDMA’s autumn survey says 64% of German additive manufacturing firms grew sales over the past year, up from 45% a year ago. But costs still top their worries. Growth is not the same as profit.

Look at the listed printer makers. In Q2, Stratasys lost $16.9M and 3D Systems lost $12.9M. Creality grew first-half revenue 13% and still swung to a loss. Digital manufacturers do a little better: Proto Labs earned $9.2M, while its 3D printing revenue slipped and its CNC and molding grew.

Against sector benchmarks, the pattern is clear. Printer makers earn machinery-level gross margins but post losses. 3D printing companies beat their sector mainly in medicine.

The profits sit in four places.

Treatments with printing inside. Align prints a mold for every Invisalign tray and posted a 71.7% gross margin in Q2. The printer is a cost line, not the product.

Medical software and services. Materialise’s medical segment earned a 31.3% adjusted EBITDA margin. The whole company earned 5.5%.

Ecosystems that sell consumables. Formlabs says it has been profitable for two years. Creality’s consumables grew 48% while printer sales were flat.

Devices priced on clinical value. Stryker has printed more than two million Tritanium implants, and its orthopaedics segment ran a 34% operating margin.

My view: margin follows the patient, not the machine. Price the outcome, own the consumable, and secure payment early. That is why Trio Labs sells finished medical parts, not printers, as founder Adam Steege explains on Episode 130.

Read the full analysis on where profitability is, with the benchmarks, and leading public companies, ending with an FAQ. Which business model would you back? Better ideas?

Hit reply and tell us.

A note from Jenny: I’m taking a few weeks of vacation. The Lattice Brief will be back on its normal schedule the week of November 2. Thank you for reading.

From 3DHEALS

• Which 3D Printing Businesses Are Profitable? A Healthcare Focus in 2026. The full analysis behind this week’s big thing: sector benchmarks, Stryker, Xometry and Proto Labs, four profitable business models, and an FAQ.
• Episode 130: 3D Print Tiny Things with Adam Steege, Trio Labs. Why Trio sells finished micron-scale metal parts for medical devices instead of printers, and when printing beats CNC and metal injection molding.
• 3D Printed Drugs Guide (updated October 2026). Background for this week’s PharmaTher and St. Jude items: processes, players, evidence and the new point-of-care rules.

Regulatory watch

• FDA clears Providence Medical’s 3D printed porous titanium cervical system (ODT Magazine, Oct 13). A 510(k) for CORUS PCSS 3D-T, a printed porous titanium version of its posterior cervical stabilization system. Same design and indications; the lattice is meant to support bone ingrowth.
• ARPA-H awards Terasaki Institute up to $19.8M to bioprint liver tissue (EurekAlert!, Oct 2). The PRINT program’s Prometheus project combines stem-cell-derived liver cells, bioreactor culture and bioprinting to make tissue that avoids immune rejection. A catch-up item we missed two weeks ago.

Clinical & research

• Bioprinted scaffolds for leg ulcers: a systematic review of clinical trials (Frontiers in Bioengineering and Biotechnology, via PubMed). University of Hong Kong authors found 8 clinical studies with 139 patients. Both randomized trials showed faster complete healing than standard dressings, with no treatment-related serious adverse events. The studies are small with short follow-up.
• Custom 3D printed shoulder prostheses after tumor resection: 30 patients at three years (Journal of Shoulder and Elbow Surgery, via PubMed). Sun Yat-sen University Cancer Center reports mean functional scores of 84% (MSTS) and 85% (ASES) at a mean 37.7 months, with one loosening and two plate exposures. Retrospective, single center.
• Vision-guided robotic bioprinting onto diabetic wounds (Advanced Functional Materials, via PubMed). A Brigham and Women’s / Harvard team paired an oxygen-releasing stem-cell bioink with an autonomous robot that prints directly onto the wound. In animal models it sped closure. Physical AI meets bioprinting.

Also this week

Point of care and pharmacy

• How a Dutch trauma center built a roadmap for printing splints in house (3D Printing in Medicine, via Bioengineer.org). Radboudumc mapped technical, workflow and regulatory barriers, with owners for each.
• PharmaTher launches a national network of pharmacy printing sites (3D Printing Industry). Starts with US 503A compounding pharmacies; it will seek emergency-readiness contracts. A follow-up to last week’s big thing.
• 3D printing and automated compounding in pediatric pharmacy (Journal of Pediatric Pharmacology and Therapeutics, via PubMed). St. Jude Children’s Research Hospital pharmacy authors on bringing both into pediatric practice.
• 3D reconstruction beats 2D imaging for pediatric kidney surgery planning (VoxelMatters). Turin, 8 children. The models were virtual, not printed; the team cited cost.

Devices and dental

• IMDEA and UPM print braided nitinol for transcatheter devices (VoxelMatters). One-step braided stents recovered over 90% after compression to half their diameter.
• SprintRay adds a scanner and compact chairside print line (Med-Tech Insights). Foundation scanner and Nano Series ship from November, subject to regional approvals.
• GC launches a hybrid ceramic resin for SprintRay’s Midas press (PR Newswire). For permanent crowns, inlays, onlays and veneers; US availability from Nov 1.
• Limber Prosthetics sells a printed leg from $3,000 (Hoodline). Smartphone scan, one-piece print in about 12 hours; about 800 devices made, per the company.

Research

• Support-bath bioprinting keeps mature human fat cells alive (Bioengineer.org). University of Stuttgart; a step toward better fat-tissue models for metabolic disease.

Industry and tools

• VDMA autumn survey: business improves, expectations cautiously positive (VDMA). 64% of German AM firms grew sales; medical technology is among the fastest-growing applications.
• UC Berkeley releases OpenCAL, an open-source volumetric printer (VoxelMatters). About $1,638 in parts, with resin from Formlabs and Prusa.
• NVIDIA open-sources a CAD modeling kernel (3D Printing Industry). USD BRep, Apache 2.0; a building block for AI-assisted design.
• A roller coaster, kidney stones and ultrasound: a decade later (Medical Daily). How a 3D printed kidney model on a Disney ride led to ultrasound devices for stones.

Get The Lattice Brief every week. We are back the week of November 2.

Subscribe to The Lattice Brief

Want to sponsor this newsletter? Contact us

The post Where 3D Printing Actually Makes Money | The Lattice Brief (10/19/26) appeared first on 3DHeals.

This week’s Lattice Brief looks at three bets on printing medicines in the pharmacy: PharmaTher’s CraftMake roll-out to US compounding pharmacies, CurifyLabs’ dose-accuracy work, and France’s first license for drug-printing cartridges. Also inside: FDA clears a patient-specific 3D-printed radiation bolus, a one-year randomized trial of printed vs zirconia crowns, and our updated 3D Printed Drugs Guide.

The big thing.

The pharmacy wants to be the factory

Three companies made the same bet in two weeks. PharmaTher says it expects the first orders for its CraftMake pharmaceutical 3D printer this quarter, with up to 50 installations in US compounding pharmacies within a year and a New Drug Application for a rare pediatric therapy by late 2028. A doctoral thesis from Åbo Akademi University and spin-off CurifyLabs reported on dose accuracy for pharmacist-dispensed gels. And France’s medicines regulator licensed MB Therapeutics to make printing cartridges as a pharmaceutical manufacturer.

The bet: 3D printing can scale in compound medicine.

The clinical case is real but thin. A 2026 review counted 10 clinical studies of printed medicines made at the point of care. Most were single-centre and short. The best known comes from Santiago de Compostela, where four children with maple syrup urine disease took printed chewable isoleucine for six months. According to the study, indexed in PubMed, their blood levels sat closer to target and varied less than on hand-filled capsules (DOI). Children and rare diseases are where tailored doses matter most, so that is where this market starts.

The business model of choice is razor and blade. Place the printer once. Sell validated formulations, cartridges and software every week.

On the regulatory front, the rules are arriving unevenly. The UK’s point-of-care framework has been in force since July 2025. FDA’s July proposal would let a distributed manufacturing network register as one establishment, but it does not cover compounding, which is where US printed doses live today.

Again, the printer is not the hard part. Batch release, adverse-event reporting and recalls across 50 sites are. Taking responsibilities for a bad batch is required to own the market.

What do you think? Is 3D printed drugs incremental improvement or transformational to the future of medicine?

We have updated our 3D Printed Drugs Guide with everything that changed since August 2025: processes, players, clinical evidence and regulation. For the people building it, listen to FABRX’s Alvaro Goyanes on Lattice Podcast Episode 112, or watch our panel with FABRX, Craft Health, CurifyLabs and NIST on demand.

From 3DHEALS

• 3D Printed Drugs Guide (updated October 2026). Processes, players, clinical evidence and the new UK, US and French rules for printing at the point of care, with a summary of everything that changed since August 2025.
• Episode 112: Automating Compounding Pharmacies with FabRx 3D Printing. FABRX co-founder Alvaro Goyanes on built-in quality checks, pediatric dosing and point-of-care regulation.
• 3D Printed Pharmaceuticals (on demand). Our panel with FABRX, Craft Health, CurifyLabs and NIST on polypills, pediatric formulations and compounding economics.
• Episode 129: Medical 3D Printing Adoption in the EU with Naomi Nathan. Dr. Naomi Nathan of Mobility Goes Additive on reimbursement hurdles for hospital point-of-care printing and building evidence through registries and multicenter studies.

Regulatory watch

• FDA clears Myrava’s patient-specific 3D printed bolus (3D Printing Industry, Oct 2). A 510(k) for a printed layer that shapes radiation dose at the skin. It is the former Ricoh 3D for Healthcare’s first clearance beyond anatomical models, made from treatment-plan files at FDA-registered point-of-care sites. Hospital printing is moving from models to devices that change treatment.
• FDA to prioritize guidance on AI and surgical robots next year (MedTech Dive, Oct 2). CDRH’s fiscal 2027 A-list puts final guidance on AI-enabled devices and robotic surgery submissions at the top. 3D printing is not on the list.

Clinical & research

• Printed resin crowns vs zirconia: a one-year randomized trial (Journal of Dentistry, via PubMed). In 56 patients at Yonsei, fracture-free survival was 78.6% for printed resin crowns vs 92.9% for zirconia, a difference that was not statistically significant. Fit and patient satisfaction were similar. Printed crowns wore about six times more, and 7 of 8 fractures were on the back-most teeth. Fine for some cases; not yet a zirconia replacement for molars.
• Printed vs thermoformed finger orthoses (3D Printing in Medicine, via VoxelMatters). In a pilot with 20 occupational therapy students, printed trigger-finger orthoses scored higher on fit, comfort and durability and cut hands-on labor. They took more total time and material cost. Small and not randomized.
• MLATE V3: open-source AI for printable scaffolds (Biofabrication, via PubMed). A Polish Academy of Sciences team released an open dataset of 2,646 samples and a free tool that predicts printability and cell response before printing, then ranks bioink formulations. Fewer failed prints, if it generalizes.

Also this week

Dental and devices

• Graphy signs a $1.3M dental resin supply deal with MegaGen (VoxelMatters). High-ceramic resin for long-term crowns. Cleared in Korea; FDA and CE marking pending.
• IOT and VisionLab sell volumetric 3D printed progressive lenses (VoxelMatters). Each lens cures in one light exposure, on sale in Spain since Oct 6.

Research

• Light-based bioprinting for clot-prone vessels in women (Science Advances, via PubMed). A Sydney perspective on patient-specific vessel models for cerebral venous sinus thrombosis and carotid web.
• 3D printed lattices that map their own damage (Engineer Live). Glasgow and Sydney locate damage to about one strut before failure. Implants are a possible future use.

Industry and physical AI

• Stryker CEO Kevin Lobo to step down (MedTech Dive). COO Spencer Stiles takes over Jan 1. Stryker is a major maker of 3D printed orthopedic implants.
• Neura Robotics brings a logistics robot to hospitals (Robotics & Automation News). Moves beds and sterile goods, leased as a service.
• The physical world is AI’s next bottleneck (3D Printing Industry). Opinion: physical AI lacks internet-scale data, so hospitals and factories will have to make it.

Community

• Bambu Lab and seven accessibility groups launch an assistive-device challenge (3DPrint.com). 24 design briefs, including from e-NABLE France and Rancho Los Amigos. Entries due Nov 15.

Get The Lattice Brief every week.

Subscribe to The Lattice Brief

The post The Pharmacy Wants to Be the Factory | The Lattice Brief (10/11/26) appeared first on 3DHeals.

This week: China’s additive manufacturing build-out and what it means for medicine, a France-licensed supply chain for 3D-printed drugs, an FDA call for new evidence pathways, a randomized trial for 3D-printed surgical simulators, two bioprinting papers, and the rest of the week in healthcare 3D printing.

The big thing

China is printing more of everything. Is that a problem?

Addireen’s new Ganzhou plant can build up to 50 metal printers a month. Eplus3D’s Beijing factory is sized for 300+ large metal systems a year. China exported 2.46 million consumer printers in four months, up 44.7%.

Medicine is following. China’s share of PubMed papers on 3D printing and bioprinting has climbed to 28% over the past decade, while the US share fell to 17%. China registered 199 printed devices by late 2024, ten times the 2020 count; the US had cleared 357+ by 2023. Chinese hospitals now publish bigger series, like a 224-patient anatomic cage study last month.

Is it all subsidy? Partly. Beijing has favored domestic machines and powders since 2018. But procurement lists do not sell millions of printers to consumers who can choose.

Intellectual property is the constant worry. A Texas jury awarded Stratasys about $27.6M against Bambu Lab, which will appeal. Millions of printers shipped while the case ran.

So is it a problem? Cheap hardware helps buyers. The risk is that the learning curve follows the volume. The West’s defensible layer is high-value applications, qualified workflows, outcomes data and talent. Tell us what you think. Read the full analysis.

Regulatory watch

• FDA seeks new regulatory science framework for innovative tech (Medical Design & Outsourcing, Sept 25). FDA’s device center wants input on evidence pathways for autonomous AI, generative AI and implants that grow with the patient. Comments close Nov 24 (docket FDA-2026-N-8563).
• MB Therapeutics cleared to manufacture cartridges for 3D printed drugs (3D ADEPT, Oct 1). France’s medicines regulator (ANSM) licensed a GMP site for drug cartridges that hospital-pharmacy printers turn into personalized doses. Printed drugs now have a regulated upstream supplier; Finland’s CurifyLabs runs a different model.
• Xenix Medical clears NanoACTIV surface for its Riva screws (Business Wire, Sept 30). A 510(k) extends a surface first cleared on Xenix’s printed titanium implants to machined screws. Not a printed-device clearance; we found no new 510(k) for an additively manufactured device this week.

Clinical & research

• Skill transfer from 3D-printed temporal bone training to cadaveric mastoidectomy: a randomized controlled trial (Otology & Neurotology). Thirty novice ENT residents in Sao Paulo. Two hours on a printed temporal bone raised blinded cadaver scores by 4.2 points. Small and single-center, but randomized evidence for printed simulators is rare.
• Airflow controlled droplet bioprinting enables high-throughput generation of iPSC-derived thymic organoids (Biofabrication). Pittsburgh swapped manual encapsulation for air-jet droplet printing: about 21,500 aggregates per mL, and functional T cells in mice. A manufacturing paper as much as a biology paper.
• 3D bioprinted human vascular organoid sheets promote functional ischemic repair (BMC Medicine). Tsinghua’s printed vessel sheets joined the host circulation and improved limb salvage in mice. Single-cell data show grafted cells remodel heavily after implantation.

Also this week

Business & manufacturing

• Healthcare growth reshapes 3D Systems’ $94.6M quarter (3D Printing Industry). Revenue was flat; healthcare grew 6.9% to $48.1M and is now about half of sales.
• Tenon Medical moves its 3D-printed SI joint screw to full launch (Ortho Spine News). The printed titanium lateral screw brought in about $1.2M during its alpha launch.
• Addireen opens Ganzhou facility for up to 50 metal AM systems a month (3D Printing Industry). Green-laser printers for pure copper parts such as AI-server cold plates.
• Carbon’s dual-cure patent survives appeal in Europe (TCT Magazine). Worth watching for resin suppliers selling into European dental labs.
• DiFusion to define a therapeutic biomaterials category at NASS 2026 (GlobeNewswire). Positioning for its ZFUZE spine material, which can be printed from filament. Company messaging, no new data.
• The speed paradox in 3D printing (Engineering.com). A Boston job shop says AI routing cut order-to-print time from four minutes to two or three.
• Meshy 7 review: how can humans keep up? (VoxelMatters). AI image-to-3D is good for concepts and decorative prints, not device-grade CAD.
• OSU adds in-situ sensing to a multi-head composite printer (3D Printing Industry). NSF-funded fiber-plus-polymer printing with machine-learning quality checks. No medical use yet.

Devices, materials & models

• Vital3D and Cleveland Clinic partner on patient-specific brain stents (NeuroNews International). A license to develop printed Y-stents for bifurcation aneurysms at about 1-micron resolution. Early stage.
• MIT and Johns Hopkins build a 3D-printed living cell collection device (VoxelMatters). Fluid shear lifts viable cells from tissue without enzymes, tested on fallopian tube samples.
• MIT develops bioresorbable batteries for ingestible devices (Medical Design & Outsourcing). A 1.84 V magnesium battery that dissolves; it powered stimulation for three days in animals. Not printed.
• 3D printing enables custom rubber gloves in smaller batches (Medical Xpress). Cranfield sprays and cures natural rubber in place, making small runs of fitted gloves viable.
• Building a beating heart: how 3D bioprinting is changing cardiac medicine (MD+DI). Minnesota’s Brenda Ogle: drug testing comes first; thickness and integration block therapy.
• ATCC wins $8.3M for organ-on-chip and organoid models (GlobeNewswire). NIAID and FDA contracts, a funding signal after FDA’s nonclinical-testing rule.

Community

• University of Nottingham brings 3D printing to hospital schools (TCT Magazine). Printers and training for 25 schools serving children with long hospital stays.

From 3DHEALS

• Episode #129: Medical 3D printing adoption in the EU with Naomi Nathan. The head of healthcare at Mobility Goes Additive on why hospital successes stall before system-wide adoption: reimbursement, evidence and Europe’s fragmented health systems.
• Next-Gen 3D Printed Orthotics and Prosthetics (Oct 15, virtual)

Get The Lattice Brief every week. Subscribe to The Lattice Brief

The post China Is Printing More of Everything | The Lattice Brief (10/4/26) appeared first on 3DHeals.

This week: an open AI model for materials that has more downloads than DeepSeek but still can’t touch a bioink, a Singapore clearance for a 3D-printed wound-care implant, three fresh bioprinting papers, and cartilage printing aboard the space station.

The big thing

AI Model for materials beat DeepSeek’s downloads. It still can’t help fill the biology gap.

At our Biomaterials Frontier event, a Johns Hopkins and NIST materials scientist Prof. Kamal Choudhary mentioned, almost in passing, that his open AI model (DiffractGPT) for materials had been downloaded more times on Hugging Face than DeepSeek. But that is hard not to notice.

Kamal Choudhary has built the tools that make AI-driven materials discovery real: an open database with 200,000 users, models that predict a material’s properties in seconds, and a “ChatGPT for materials” that plugs into Claude. Hand one an X-ray pattern and it will propose the atomic structure behind it, including for compounds that do not exist yet.

And almost none of it can help develop biomaterials. At least not yet.

That is the uncomfortable part, and Choudhary said it himself when the moderator Craig Rosenblum asked. The AI is fluent in the physics of hard, crystalline materials. It knows little about biology: how it degrades, whether cells like it, whether it heals. Good data barely exists, and the experiments that would create it are the slow, expensive bottleneck.

Which is exactly why it is an opportunity.

The moat in (bio)materials science is not just the model. It will be the biological data few have, and the company patient and strategic enough to generate it.

Read our more in-depth review and analysis based on Dr. Choudhary’s work at Hopkins here, and see where the money goes next, in the full piece: More downloads than DeepSeek: AI Model for Materials (Expert Corner) →

Regulatory watch

• UltiMaker and Bioactivx: a 3D-printed wound-care implant clears Singapore’s HSA — Bioactivx’s synthetic, animal-free Bioactiv Matrix, printed on UltiMaker systems in an ISO 13485 cleanroom, won Singapore HSA approval, with US, EU, Australia and ASEAN filings pending. A proof point that additive manufacturing can meet certified end-use device standards, not just prototyping. (This is a Singapore HSA clearance, not an FDA action; no new FDA 510(k) AM clearances surfaced this week.)

Clinical & research

• In-situ bioprinting builds a blood supply inside new bone (Acta Biomaterialia · via PubMed) — Targets bioprinting’s core bottleneck, keeping thick tissue alive by printing its vasculature in place. Preclinical (mouse).
• A bioprinted dentin-pulp model that mineralizes and grows vessel-like channels (Biofabrication · via PubMed) — Stiffer zones drive mineralization while softer zones form vessels, a tunable test bed for regenerative dentistry. In vitro.
• A 3D-printed scaffold plus engineered stem cells regrows injured nerves (Bioactive Materials · via PubMed) — Scaffold-guided peripheral-nerve repair restored function in a preclinical model. Proof of concept (rat).

Also this week

• An AI database pairs drugs with excipients for on-demand pharmacy printing (VoxelMatters) — University of Mississippi with Colorcon; in development, not yet deployed.
• Cartilage bioprinting tops the research schedule aboard the ISS (NASA) — Reported microgravity crew activity, not a published result.
• ‘Subvoxel’ multimaterial bioprinting co-extrudes several bio-inks at once (Technology.org) — Demonstrated in cultivated meat; the multimaterial technique may transfer to tissue engineering.

From 3DHEALS

• Biomaterials & 3D Printing in Healthcare: event recap — The write-up by our intern Peter Hsu from the Biomaterials Frontier panel behind this week’s lead.
• Episode 127: Lean compliance for medical 3D printing, with Erik Boelen — The latest Lattice Podcast, on making quality systems workable at the point of care.
• On-demand course: AI Updates for 3D Printing and Bioprinting — Goes deeper on AI across the print-to-clinic workflow.

Subscribe to The Lattice Brief

The post AI for Materials Has A Biological Gap | The Lattice Brief (9/19/26) appeared first on 3DHeals.

This week’s Lattice Brief asks whether in-house hospital 3D printing is really going mainstream, or just thriving inside well-funded academic and government-backed centers. A five-year survey of European neurosurgeons shows printing moving decisively in-house, and increasingly into implants, even as a candid talk with a private-practice orthopedic surgeon suggests the everyday clinic hasn’t followed. Around that question, we cover the week’s standards and regulatory moves; three peer-reviewed advances, from a human jawbone-regeneration cohort to cartilage regrown in animals and a touch-sensing prosthetic skin; and two new pieces from 3DHEALS on metamaterials and university technology transfer.

The big thing

Will in-house 3D printing really scale?

A European survey says hospital printing moved in-house and up to implants. A veteran orthopedic surgeon says he barely touches it. So, what is the truth?

This week’s most consequential medical 3D printing story is a shift in who makes the devices. A five-year survey of European neurosurgeons, published in the International Journal of Bioprinting and covered by 3D Printing Industry recently, found departmental printing moved decisively in-house between 2020 and 2025. Neurosurgeon-led printing rose from 0% to 20.68%; reliance on an outside printing company fell from 21.81% to zero; implant fabrication climbed from 0% to 27.58% of reported uses. Caveat: two surveys, neurosurgery only. Several points still stand out:

1. Outsourcing 3D printing dropped to zero. In-house centers do win on turnaround, vendor markups, surgeon control, quality assurance, and data privacy, but zero is still surprising. I have observed biomedical engineers who used to work for vendors eventually end up in a hospital 3D printing center, working more intimately with the clinicians. Perhaps, this is the Way.
2. The cost paradox: About 80% of respondents reported better per-model cost efficiency due to cheaper desktop printers, cheaper materials, no vendor markups. Capital expenditure and staff time remain the top barriers. Only ~32% of departments received increased administrative funding or dedicated institutional budgets since 2020, highlighting a gap between clinical enthusiasm and hospital financial backing.
3. Knowledge gap: The hardware and software questions drew a striking share of “unknown” answers. In Figure 1K, regarding printing technique, “Unknown” represents the single largest category (~40–50% of responses) in both 2020 and 2025. Worse, it seems the percentage of surgeons aware of the software used is decreasing over time in these institutions. While one might imagine physician champaigns (and even “technical physicians”) now work closer with the engineering team than ever, the reality might be siloed departments or initiatives relying on individual “power users”. Maybe the technical mechanics don’t matter to day-to-day clinical work. Or maybe that gap is exactly what limits a program’s longevity.

Back in 2017, 3DHEALS published a cost model for an in-house hospital printing service, using a cardiothoracic example with a $300,000 Stratasys Objet500 Connex3, roughly $367,600 in acquisition cost, and a 125-print breakeven that left year one in the red. The verdict then: build it only with real volume and patience.

So, who cleared that bar? The survey’s respondents were mostly university hospitals, and its authors concede the pattern may widen the gap between academic and community centers. The other showcase examples of compliant in-house implant manufacturing are both public money: the U.S. Walter Reed military medical center, the first point-of-care institution with an FDA 510(k) clearance for an implant it makes itself, and Madrid’s public Hospital 12 de Octubre, now ISO 13485-certified. In-house printing is growing, but so far inside academic and government-funded systems with the staff, capital, and quality apparatus to carry it.

Then there’s the ground truth. Last week I asked a seasoned private-practice orthopedic surgeon how often 3D printing enters his routine knee cases. His answer: rarely and only for the genuinely complex ones. Feel free to do your own field survey. That’s striking, because orthopedics is supposedly the field where 3D printing already won: the major implant makers have printed porous titanium at industrial scale for over a decade. But that is centralized manufacturing the surgeon never experiences as “3D printing.” At the point of care, for the everyday case, patient-specific printing can still feel more like a marketing term than a tool.

Our view: “Point-of-care 3D printing” has three tribes. One thrives in academic and public institutions, one inside the implant industry’s own factories. The third and largest, the community private practitioner isn’t yet totally on board. The real question was never whether this group will adopt 3D printing (in-house or outsourced) but when reimbursement, standards, and outcome evidence will finally line up.

If you work in orthotics and prosthetics, help our super fan Dr. Jade Ward map the field: fill out our short O&P survey.

Sources: Özdemir D, Middelkamp M, et al. “The development of three-dimensional printing in neurosurgical departments across Europe: A five-year perspective.” Int. J. Bioprint. 2026;12(3):026090076. DOI: 10.36922/IJB026090076. Trade coverage: 3D Printing Industry, Sept 3, 2026. Historical reference: 3DHEALS, “In-House Cost Consideration for 3D Printing for Surgical Applications, Part 2,” 2017. Orthopedic observation: author’s own conversation, Sept 2026.

Regulatory watch

• Advancing European standards and regulations for 3D bioprinting — Trends in Biotechnology – the European Commission’s Joint Research Centre and CEN-CENELEC argue clear standards and regulatory frameworks are the gating step to safe clinical bioprinting. (No new FDA 510(k) additive-device clearance surfaced this week.)
• ASTM International launches Critical and Emerging Technologies (CET) Division — Additive-manufacturing standardization stays the flagship as ASTM broadens its remit; standards convergence is a gating factor for medical AM qualification.

Clinical & research

• Alveolar bone regeneration using 3D-printed, patient-specific, resorbable PCL scaffolds (J. Clin. Periodontol.) — A 10-patient prospective cohort – a rare human clinical readout, with mean regenerated volume ~112% of the original defect.
• BIO INX material enables functional cartilage regeneration in a rabbit study (European Polymer Journal) — First in vivo proof for multiphoton-printed DEGRAD INX microscaffolds; repaired tissue reached ~91% of native cartilage thickness.
• 3D-printed electronic skin gives prosthetics touch and temperature sensing (Cell Reports Physical Science) — A scan-model-print e-skin reportedly senses at ~10x the resolution of commercial glove sensors – a step toward truly sensate prosthetics.

From 3DHEALS

Metamaterial and 3D Printing — Jenny Chen on why metamaterials – structures whose properties come from designed micro/nano geometry rather than their base material – are a natural partner for 3D printing: implants tunable for strength and resorption, higher-sensitivity printed sensors, and more responsive soft-robotic surgical tools.

The Lattice, Episode 125 – Inside Technology Transfer at UCLA with Mark Wisniewski — Innovation as a chess game: UCLA’s Mark Wisniewski on how technology transfer turns a university-lab idea into a company, a breakthrough, or a treatment – essential listening for anyone pushing medical 3D printing research toward the clinic and the market.

The post Will in-house 3D printing really scale? |The Lattice Brief (9-13-26) appeared first on 3DHeals.

This week: why the real frontier in 3D-printed biomaterials is regulatory legibility, not geometry; European neurosurgery quietly moves its printers in-house; a first-in-human 3D-printed cartilage implant; fresh calls for bioprinting standards; and titanium lattices that float. Plus our free Sept 10 Biomaterials Frontier event.

The big thing

The material is the frontier now

For a decade, 3D printing in medicine was a story about shape — patient-specific anatomy, geometries no mold could make, “complexity for free.” In 2026, the center of gravity has moved. The question that decides whether a printed part reaches a patient is no longer “what shape can we print?” but “what material can we print, and will a regulator accept it?” Call it the move toward regulator-legible material systems.

“Legible” is not a metaphor. A regulator approves evidence: documentation that a material behaves the same way every time, degrades on a predictable schedule, releases nothing harmful, and is made to a specification you can point to. For years, printed biomaterials failed that test — beautiful one-off scaffolds with no agreed test methods, batch-to-batch drift, and properties that shifted with every machine setting. Brilliant science a reviewer couldn’t sign off, and no basis for a product.

The reason they are hard to read is that, in additive manufacturing, the material and the process are inseparable. A resin cured layer-by-layer on a specific printer, wavelength, and post-cure is effectively a different material each time. So the field now talks about material systems, feedstock, validated print parameters, post-processing, sterilization, and standardized tests, all made legible through standards such as ISO/ASTM 52900, ASTM F42 and F04, ISO 10993, and ISO 13485. We walk through what each of those standards actually asks of a printed material and where the gaps still are in the full article.

This should be an investment thesis, not a chore. The moment a printed biomaterial becomes regulator-legible, it crosses from research risk to a fundable product. With the healthcare 3D-printing market projected to reach roughly $33 billion by 2031, the binding constraint could shift from the printer to the material.

That is the subject of our next event. “Biomaterials Frontier for 3D Printing,” a free 3DHEALS virtual session on September 10, 2026, convenes the people making materials legible fastest — a bioresorbable-polymer and ASTM standards leader, a human-collagen biofabrication founder, an AI materials-discovery researcher, and more.

Register free: 3dheals.com/biomaterials-frontier

Regulatory watch

• Nanochon begins first-in-human study of its 3D-printed Chondrograft knee implant — The 3D-printed cartilage implant, which holds FDA Breakthrough Device Designation, treated its first patient; it targets “pre-replacement” knees. Not a 510(k), but the week’s clearest AM-device regulatory milestone. (Sep 3)
• Advancing European standards and regulations for 3D bioprinting — A Trends in Biotechnology perspective argues that clinical and preclinical adoption of 3D bioprinting hinges on developing European standards and a regulatory pathway. Peer-reviewed. (Sep 3)

Clinical & research

• European neurosurgery survey finds 3D printing shifting in-house as implant use grows (Int. J. Bioprinting / 3D Printing Industry) — 2020-vs-2025 survey: neurosurgeon-run printing rose from 0% to ~21%, external providers fell to zero, and implant fabrication climbed from 0% to more than a quarter of departments — raising the quality and regulatory stakes as hospitals become manufacturers.
• Three-dimensional bioprinting in reconstructive plastic surgery: a comprehensive review (Cells) — Maps translational readiness tissue by tissue — skin, cartilage, bone, osteochondral, vascularized and craniofacial constructs — with bioink-selection guidance. Peer-reviewed.
• Systematic review of 3D-printed surgical devices for austere environments (Frontiers in Medical Technology) — Imperial College London and UK Defence Medical Services reviewed 15 studies and found evaluation wildly inconsistent — little standardized strength testing, sparse sterilization data, no biocompatibility testing — and propose an ISO/ASTM-aligned framework. Peer-reviewed.

From 3DHEALS

The Lattice Podcast, Ep. 125: Inside technology transfer at UCLA with Mark Wisniewski — How university tech transfer moves medical innovation from the lab bench toward a fundable product — a fitting companion to this week’s “research risk to product” theme.

Also this week

• How RMIT researchers made 3D-printed titanium float on water — Foam sealed inside the hollow struts of Ti-6Al-4V lattices makes the first buoyant metal lattice. The demo is a marine buoy, but the hollow-strut titanium-lattice method maps onto load-bearing implant design. (Sep 4)

Subscribe to The Lattice Brief

The post The material is the frontier now| The Lattice Brief (9/5/26) appeared first on 3DHeals.

This week: why clearing the FDA is not the same as getting paid for a 3D-printed stent, a world-first metamaterial bone prosthesis out of Madrid, fresh bioprinting and bone-repair research, and 3DHEALS’s Biomaterials Frontier event on September 10.

The big thing

A better 3D-printed stent is the easy part. Getting paid is the hard part.

New York University’s newest stent, BRIDGE, is a good device. It is 3D-printed and biodegradable, built to drain gastric leaks after weight-loss surgery. Its lattice drains about twice as much, bends far tighter without kinking, then dissolves with no removal endoscopy. So, if I am the patient, this is a better device. In US medical devices, being “better” is just the price of admission, not the payout. As our recent piece focusing on reimbursement puts it, better isn’t billable. Entrepreneurs beware.

Start with who gets paid. Medicare pays for the procedure, not the stent. A better bundled supply inherits the price of the thing it replaces. Endoscopic leak drainage doesn’t even have a billing code that fits, with cases falling back on a pseudocyst code or an “unlisted” one. A 3D-printed stent adds “nothing extra” just for being better. Furthermore, a stent that dissolves removes the retrieval endoscopy that a doctor currently bills. So, the first buyers are integrated, bundled-payment systems that keep the savings, and not fee-for-service proceduralists. Healthcare economics in America is complicated. A regular mental exercise on reimbursement early in a device’s life cycle could protect innovators and investors from future heartaches. Similar evaluation will be equally important to a device’s viability in other global markets, depending on the target patient population. With a trend toward point-of-care 3D printing in healthcare systems, in-house production of small batches of innovative devices could be economically viable. Read our case study on this and let us know what you think.

One hero of this story we did not talk much about is the biodegradable feature of this drainage stent. The combination of 3D printing design plus a stereolithography-printable biodegradable resin made the stent a differentiated device with a defensible “moat.” However, this moat also carries the most risk. Acidity, degradation profile, mechanical properties, softness versus hardness, immunogenicity, and thrombogenicity are all intricately related to the materials science within a new device. The industry learned that the hard way with Abbott’s Absorb bioresorbable coronary stent, which was withdrawn in 2017 after safety signals. Granted, something in the heart carries higher risk than in the gut. Ultimately though, what earns payment and what earns trust are the same thing: good outcomes across real patients.

That said, we will highlight the exciting advancements made in 3D printable biomaterials in 3DHEALS’s next virtual event, Biomaterials Frontier, on September 10. This world-class panel covers topics not just on bioabsorbable materials and relevant applications (like breast implants for lumpectomy), but also metamaterials for orthopedic implants, human collagen produced in bioreactors for bioprinting, ML/AI for new biomaterial development, and more.

Regulatory watch

No new FDA 510(k) clearances for additive-manufactured devices this week.

Clinical & research

• A 3D-Printed Microvascular Surgery Training Platform With High-Fidelity, Biomimetic Properties (Small (PubMed)) — A UC San Diego group prints suturable, patient-specific vascular grafts with a machine-learning-tuned bioink. The near-term use is low-cost microsurgery training; the longer game is personalized vascular repair.
• Extrusion bioprinting of FibMA-fibrin semi-IPN hydrogel filaments for enhanced skeletal muscle cell alignment (Biofabrication (PubMed)) — A fibrin-based bioink prints muscle-cell filaments that align on their own, with no sacrificial polymer and no second gelation bath. A step toward printable, functional skeletal muscle.
• Instrumentalized 3D printed scaffolds enable bone regeneration and fracture healing monitoring in critical size bone defects (APL Bioengineering (PubMed)) — 3D-printed bone scaffolds with built-in sensors both heal critical-size defects and report on the healing. Dynamization improved union in the animal model.

Also this week

• Gregorio Marañón Hospital Implants World’s First Personalized Metamaterial Bone Prosthesis (AdvancedManufacturing.org / SME) — A Madrid hospital designed it, printed it in titanium in-house, and implanted what it calls the first personalized metamaterial bone prosthesis, saving a sarcoma patient’s leg.
• 3D-Printed Expandable Wedge Spacer Shows Promise for Atlantoaxial Reduction (3D Printing in Medicine) — An expandable titanium spacer cut the force needed to realign the C1-C2 vertebrae by about 70% in a patient-specific test model. Preclinical.
• 4D Printed Implants Could Make Tissue Reconstruction Less Painful (3DPrint.com (Mass General Brigham / UW-Madison)) — A 4D-printed hydrogel expander swells over weeks on its own, aiming to retire the saline-injection balloon used in breast reconstruction.
• Team effort puts 3D anatomy models in the hands of health care students (Yakima Herald-Republic) — Two Washington universities make low-cost, markable anatomy models to widen access for health-training programs.
• Why Silicone 3D printing still struggles to find its place in healthcare (3D ADEPT) — A clear-eyed read on why a well-suited material still lags in healthcare: thermoset chemistry, Class III hurdles, and no process standard.
• Materialise Reports Second Quarter and Half-Year 2026 Results (Business Wire) — Q2 revenue EUR 70.1M, up 8.1%; the Materialise Medical segment grew 12.2%, and the company raised full-year operating-profit guidance.
• Hike Medical Raises $22.5 Million As AI and 3D Printing Platform Targets $100 Billion Medical Device Market (Pulse 2.0) — An AI-plus-printing platform for orthotics, prosthetics, and durable medical equipment raised $22.5M. The delivery-time and remake-rate gains are the company’s own figures.
• AI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 Billion (BCC Research) — A market-research firm frames AI plus bioprinting as an investment category. Positioning, not primary research.
• HeyGears G1 Passes $14M on Kickstarter with Full-Color 3D Printing (3DPrint.com) — Off-beat: a consumer full-color desktop printer from a dental-roots company. Not a medical device, but a marker on where printing hardware is going.
• NASA-backed research makes 3D printed cookie out of plastic waste (VoxelMatters) — Off-beat: engineered yeast turns PET waste into edible protein for a NASA Deep Space Food Challenge project. Food and space, not healthcare.

From 3DHEALS

• Better isn’t billable: how a new 3D-printed medical device actually gets reimbursed — Jenny Chen, M.D. walks through why a better, cleared device still may not get paid, using the BRIDGE stent as the worked example.
• Biomaterials Frontier (virtual event, September 10) — A panel on bioabsorbables, metamaterials for orthopedic implants, bioreactor-grown collagen for bioprinting, and ML/AI for new biomaterials.
• The Lattice Podcast, Ep. 121: Absorbable biomaterials with Dr. Rao Bezwada — The chemistry of absorbable polymers: degradation, strength, and why timing decides safety.
• Guide: 3D-printed stents — The 2023 primer on stents beyond the artery: airways, gut, biliary, and ureteral tubes.

Subscribe to The Lattice Brief

The post Getting paid is the hard part | The Lattice Brief (8/30/26): appeared first on 3DHeals.

This week, the theme is function. The field is quietly shifting from printing shapes to printing behavior, letting geometry and materials, not just the device, do the medical work. Our big thing makes the case at its most literal: a 3D-printed lattice that could reinvent the artificial lung by treating architecture as the active ingredient. The same logic runs through the rest of the issue: bioprinted tissue that grows its own blood supply, an FDA-cleared denture resin winning on toughness rather than novelty, $30 patient-shaped MRI coils, and open-source prosthetics built to reach the people standard devices miss. We close in orbit with a podcast on why microgravity makes tissue easier to build, featuring CSO of the International Space Station, Dr. Michael Roberts, and an event on where biomaterials go next.

The big thing

The artificial lung may be an architecture problem

I would not call ECMO “artificial lung” just as I would not call dialysis “artificial kidney”. That said, ECMO is the closest thing we have: a machine that oxygenates blood in place of the lungs, but only for a while. For half a century, the artificial lung has been a bundle of hollow fibers: pack thousands of gas-permeable straws into a housing, push blood past them, and let oxygen diffuse in. It works well enough that ECMO keeps the sickest patients alive, and well enough that the ECMO machine market still runs almost entirely on hollow-fiber oxygenators. The total market is roughly $0.65 billion in 2025 and is projected to reach ~$0.86 billion by 2030. “Well enough” is the tell. Blood threads unevenly through a fiber bundle, pooling in dead zones where it clots. This means that patients would need continuous anticoagulation, which makes them bleed. Additionally, the device stays outside the body as a bridge rather than a destination. A German-Dutch team led by Hannover Medical School’s Bettina Wiegmann recently proposed in the August issue of Advanced Materials that a 3D-printed gas-exchange membrane with a triply periodic minimal surface (TPMS) could solve the problems posed by hollow fibers and advance our ambition of an artificial lung. TPMS is a continuous, mathematically defined lattice that dictates where blood flows, how thin the diffusion barrier is, and where clots can’t gather. In simulation, optimized designs moved on average up to ~88% more oxygen than conventional fiber bundles, with smoother flow and fewer stagnation zones. That said, while architecture is the central theme in this paper, the researchers also included additional design elements, from printable silicone elastomers that can be made into membranes thin enough to breathe; a living endothelial lining made the membrane less thrombogenic; and an ambitious CT-derived geometry hints at a lung shaped to fit one patient’s chest.

The holy grail here is an implantable lung for the many and increasing number of end-stage patients who will never receive a donor organ. However, if the architecture is the active ingredient, then the incumbents’ fiber-winding lines look more like a legacy asset than a moat. History suggests the architecture is the easy part. ALung Technologies spent 25 years and north of $100 million turning a University of Pittsburgh lab device into the Hemolung Respiratory Assist System — FDA De Novo clearance in late 2021, acquired by LivaNova roughly six months later, and still a niche CO2-removal box rather than a lung. Draper has been building biomimetic microfluidic oxygenators since 2010 on NIH and Army money and reached clinical-scale flow in 2023 at 750 mL/min, the highest reported for a microfluidic device — elegant physics, no product. United Therapeutics and 3D Systems, partners since 2017, printed a lung scaffold of 44 trillion voxels that demonstrated gas exchange in animals in 2022 and predicted human trials “in under five years”; that window has quietly closed. OptiLung, a Texas-based early-stage startup, is commercializing a single-part, single-material 3D-printed oxygenator with a branching manifold that routes blood through vasculature-like channels and eliminates stagnant zones where hollow fibers clot. However, while the geometry is solved on the bench, questions about biocompatibility, efficacy, scalability, reimbursement, and more remain to be answered. Caveats abound here too: the results of this paper are in silico, early-stage, and no patient has been near it. Nonetheless, this is a paper worth reading and thoughts worth contemplating. Sources: Pflaum et al., “From Fiber Bundles to Architected Membranes,” Advanced Materials (2026), doi.org/10.1002/adma.74361.

Regulatory watch

• Carbon’s DB 4000 denture base resin clears FDA and meets ISO 20795-1 (Hi-Impact) — An FDA-cleared, ISO 20795-1 high-impact resin for 3D-printed dentures on Carbon’s M-Series; the company reports a work of fracture ~31% above the category leader and 97% global accuracy within 130 microns. (Company press.)

Clinical & research

• Bioprinted vascularized soft-tissue flaps with an integrated arterial-venous loop (Cell Biomaterials, via PubMed) — A muscle-and-fat flap bioprinted with its own printed arteriovenous loop for direct microsurgical hookup – a concrete step toward vascularized reconstruction.
• 3D-printed dissolving microneedles co-deliver curcumin and 5-FU for skin cancer (Advanced Healthcare Materials, via PubMed) — One-step DLP printing loads both drugs into a single dissolving array (>95% insertion); a formulation-and-process result, with biological validation still to come.
• A validated 3D-printed liver model for endoscopic-ultrasound (endo-hepatology) training (Surgical Endoscopy, via PubMed) — A CT-derived, tissue-free liver phantom showed strong content and face validity (index 0.85) across 16 endoscopists; vascular realism is the acknowledged next fix.
• miRNA-programmed spheroids bioprinted for vascularized bone regeneration (Chemical Engineering Journal) — Penn State placed stem-cell spheroids carrying bone (miR-148b) and vessel (miR-210) cues into scaffolds, improving vascularized bone repair in mice.

Also this week

• Recycled medical-grade plastics as a route to neurosurgical tools and implants in LMICs (Cureus) — Narrative review makes the case that locally recycled, low-cost plastics can widen access where imported filaments are cost-prohibitive.
• Custom 3D-printed MRI receive coils, ~$30 and under 10 minutes (Digital Journal) — USC prints patient-shaped coils reporting ~4x more image contrast than commercial units – aimed first at infants.
• Rady Children’s 3D lab models donor-heart fit for pediatric transplants (KPBS) — Physical and virtual models test whether a larger donor heart fits a child’s chest, working around the pediatric-donor shortage.
• Stratasys renews its 3D-printed prosthetics partnership with Limbitless (PlasticsToday) — A 12-year collaboration extends with a sustainability focus (a certified pre-owned printer) and STEAM access.
• TOM: 1,200 open-source, zero-patent assistive-tech designs (3D ADEPT) — Tikkun Olam Makers cuts assistive-device costs 80-99% using volunteer designers and desktop printers across 36 countries.
• Adelaide University to build multi-material biomimetic dental training models (VoxelMatters) — An AU$800K, 18-month project with Fusetec and Australia’s AMCRC to replicate how tissue behaves during procedures, not just its anatomy.
• A bioactive 3D-printing ink from Tel Aviv University (3DPrinting.com) — Holds print precision while intrinsically promoting cell adhesion and adding antibacterial activity.
• When will bioprinting become a therapy? A regulatory reality check (Frontiers in Bioeng. & Biotech.) — Review argues the path to the clinic runs through regulatory and operational hurdles, not just bench science.
• An undergraduate tunes a 3D-printing polymer for safer implants (VCU News) — VCU’s Jazlyn Lopez Silva is refining an implant-safe printing material; fibroblast testing is next.

From 3DHEALS

Podcast: Bioengineering in microgravity, with Dr. Michael Roberts (ISS National Lab) — Episode 123 of The Lattice Podcast: the ISS National Laboratory’s chief scientist on why removing gravity removes the scaffold problem that makes thick, vascularized tissue so hard to bioprint on Earth – from Redwire’s BioFabrication Facility to Auxilium’s orbital nerve-repair implants.

Event (Sep 10): Biomaterials Frontier — A 3DHEALS webinar on the defining shift of 2026 – from printing structure to printing function – convening researchers, founders and industry leaders across soft function-first bioresins, ion-releasing ceramics and bioactive glass, and titanium and titanium-tantalum lattices. Register to attend.

Subscribe to The Lattice Brief

The post Is the Artificial Lung an Architecture Problem? | The Lattice Brief appeared first on 3DHeals.

The Lattice Brief is 3DHEALS’ weekly intelligence roundup on healthcare 3D printing, bioprinting, biomaterials, and dental additive manufacturing. This week (August 14, 2026): ultra-tough and programmable 3D-printing materials from EPFL and Oak Ridge, an AI-guided new approach methodology (NAM) screening glioblastoma drugs in 3D-bioprinted tumor models, sub-10-micron bioprinted capillaries, Graphy’s takeover of dental-imaging maker Ray, and healthcare leading additive manufacturing’s latest earnings — plus upcoming 3DHEALS events on NAMs and biomaterials.

The big thing

Methods

A printed brain-tumor (GBM) model and an AI algorithm just did an animal study’s job

At the University of Southern California, a team paired a positive-unlabeled machine-learning model with a magnetic-field-guided 3D bioprinting platform to screen ultrasound-activated drugs in physiologically realistic glioblastoma (GBM) spheroids. GBM is one of the most deadly and devastating brain tumors, with no cure and high morbidity. (John McCain, Ted Kennedy, who suffered this terminal disease.) This New Approach Methodology (NAM) surfaced two already-approved drugs: carboplatin and memantine, that outperformed standard-of-care temozolomide under low-intensity pulsed ultrasound (PLOS ONE).

The result worth noting isn’t the two drug hits; it’s the workflow. A printed human-tissue model plus a computational screen did the kind of triage that has historically meant animal studies. This workflow is faster, cheaper, and in a system built from human cells rather than a mouse standing in for one. That is the practical shape of the FDA Modernization Act’s push toward human-relevant preclinical models. That said, caveats apply. This is one disease model, one organ system, one lab, one screen; sonodynamic therapy is early, and “beat temozolomide in a spheroid” is a long way from a clinical endpoint. If you are a skeptic of NAMs, you are not alone. A recent Economist article astutely pointed out that we might never completely abandon animal models. NAMs still face the validation and regulatory-acceptance questions that separate a promising in vitro result from a decision regulator will actually rely on. This is precisely the conversation 3DHEALS is hosting Next Thursday on August 20, New Approach Methodologies: From Theory to Validation. The more curious minds can also check out our recent podcast with Dr. Lowry Curley on this topic.

Materials

The most interesting thing in medical 3D printing right now is the material

For a decade, medical 3D printing mostly sold geometry. This week, albeit quiet, is filled with material focused news. At the research frontier, the printed object is learning to do more than hold a shape. EPFL’s double-network granular elastomers are 3D-printable rubbers with up to 15x the fracture toughness and 3x the fatigue resistance of comparable elastomers (Science Advances), durability that matters for anything meant to flex inside the body for years. A Pusan National University–Oak Ridge team printed a smectic liquid-crystal-elastomer ink whose molecular alignment switches mid-print, so a single filament can be programmed to elongate or contract on heating (Nature Communications). Toughness and actuation, decided at the slicer.

At the other end, call it commoditization, 3D printing materials are crossing from novelty into standardized, qualified systems. Axtra3D and Keystone’s KeyPrint brand put KeySplint Hard Clear, a biocompatible resin, onto the Lumia X1. The unglamorous, biocompatibility-qualified material work now reaches chairs and clinics. And Sinto Advanced Ceramics Europe cleared an ISO 9001:2015 audit with zero non-conformities (3D Printing Industry), the quality bar that lets technical ceramics enter regulated sectors including medical technology. Even the deal-making is organizing around materials. Graphy, a shape-memory-alloy clear-aligner-material maker in South Korea, is taking control of dental device company Ray to push its aligner materials across Ray’s roughly 70-country installed base (BigGo Finance). The materials company is buying the hardware, not the reverse. While the dollar amount is small compared to its U.S. counterpart, interested readers may appreciate the corporate drama on display. Put together, it is the biomaterials thesis in miniature: from printing structure to printing function, and from lab novelty toward regulator-legible material systems. The Chemists rule the world! Stay tuned for the highly anticipated 3DHEALS September 10, Biomaterials Frontier event, where we aim to update our audience where biomaterial innovations are.

Regulatory watch

• No new additive-device 510(k) clearances this week — A quiet week at the FDA for AM devices; the regulatory signal was upstream (below). No DARPA or ARPA-H 3D-printing activity either.
• PharmaTher establishes PERSONALIZ3D — A personalized-medicine platform pairing telehealth prescribing with a pharmacy-based pharmaceutical-3D-printing network for compounded medications, framed against recent FDA advisory-committee peptide recommendations. Pre-commercial, but a clear regulatory-tailwind bet.

Clinical & research

• Hybrid bioprinter creates capillary networks narrower than 10 micrometers (Nature Chemical Engineering) — Vascularization is bioprinting’s core bottleneck; capillary-scale channels edge printed tissue toward something that can actually stay alive.
• Scalable 4D biofabrication of scaffold-free, bone-forming callus implants (Trends in Biotechnology) — Scaffold-free constructs that ossify into real bone with marrow, scaled in a bioreactor toward human-sized implants – a translational step for bone regeneration.
• Volumetric bioprinting controls optogenetics deep inside hydrogels (Advanced Materials) — Remote, light-triggered control of cells inside centimeter-scale printed constructs – programming biology, not just structure.

Also this week

• Onkos Surgical reaches 1,000th patient-specific My3D pelvic implant case (VoxelMatters) — An adoption signal for FDA-cleared personalized implants; 350+ US institutions now use the platform for complex pelvic reconstruction.
• Singapore General Hospital’s point-of-care virtual-surgical-planning program (3D ADEPT) — How an in-house VSP + clinical-3D-printing service runs under a full medical-device quality-management system.
• 3D-scanned full-arch dentition vs 3D-printed models: accuracy across printers (Cureus) — In vitro study finds printed dental models within clinically acceptable limits across printer/resin combinations.
• Axtra3D and KeyPrint launch biocompatible KeySplint Hard Clear for the Lumia X1 (3DPrint.com) — A biocompatible dental resin reaching real chairside/lab workflows (also touched on in The big thing).
• 3D printing financials: 3D Systems, Prodways, and Align build on momentum (3DPrint.com) — Healthcare is the strongest AM end market – 3D Systems’ Med Tech grew 20%+ and Align posted record revenue.

From 3DHEALS

• New Approach Methodologies: From Theory to Validation (Aug 20) — Our next virtual event – the validation and regulatory-acceptance questions behind human-relevant preclinical models.
• Biomaterials Frontier (Sep 10) — From printing structure to printing function – where biomaterial innovation is heading.
• Podcast Ep. 122: New Approach Methodologies (NAMs) with Dr. Lowry Curley — Brain organoids, animal-testing alternatives, and what NAMs mean for drug development.

Subscribe to The Lattice Brief

The post The Lattice Brief: 3D Printing Materials, NAMs & Dental M&A appeared first on 3DHeals.

This week in healthcare 3D printing and 3D technologies: the FDA cleared the first 3D-printed implant made at a point-of-care institution, as Walter Reed’s 3D Medical Applications Center and 3D Systems turned a hospital into a cleared device manufacturer. Plus peer-reviewed bioprinting advances in vascularized bone and a breast-cancer tumor model, a patient-specific PEKK chest-wall reconstruction, catheter and pharmaceutical 3D printing of personalized peptides, and the latest on New Approach Methodologies (NAMs) and dental 3D printing from The Lattice podcast.

The big thing

The hospital becomes the manufacturer

On July 28, 3D Systems announced that Walter Reed National Military Medical Center’s 3D Medical Applications Center (3D MAC), working with the Defense Health Agency, had won FDA premarket clearance for its Titanium Cranial Plate (TCP) System. The implants would be used to treat U.S. active-duty personnel and fighters suffering from traumatic head injuries worldwide. This would be the first FDA-cleared implant ever granted to a point-of-care institution. This is also the first time a hospital crossing the line from care provider to cleared device manufacturer, inside its own walls.

That line has been blurry for years. The FDA regulates the manufacturing process and its output, not the printer; its 2021 discussion paper sketched models for producing devices at the point of care but left the framework famously unsettled. A cleared implant from a hospital-run lab would be the first hard data point on what “compliant” looks like in practice.

The commercial signal is there. Point-of-care is becoming a business. The same week, 3DPrint.com reported Ricoh selling its FDA-cleared, point-of-care patient-specific device unit to a management buyer who rebranded it Myrava (stay tuned for our upcoming podcast with Myrava soon). This serves as evidence that the segment is worth owning as a standalone company. In Europe, a Madrid public hospital became a certified device manufacturer under EU rules. What’s more interesting is the fact that vendors like 3D Systems that can carry a hospital from concept to clearance are also selling regulatory capability as much as printers.

Clinically, the case for in-house patient-specific implants is maturing. According to PubMed, a 2026 University of Basel study with 3D Systems showed point-of-care printing of functionalized PEEK cranio-maxillofacial implants within clinically acceptable accuracy. The promise is faster, better-fitting reconstructions for the patient in front of you.

Overall, this is an encouraging piece of news to all in medical 3D printing. However, whether it opens the floodgates or stays a well-resourced military exception is the question worth watching.

Regulatory watch

• First FDA-cleared implant from a point-of-care institution (Walter Reed 3D MAC Titanium Cranial Plate System) — 3D Systems-enabled 510(k) cleared Jul 28; the week’s one additive-manufactured clearance (and the subject of The big thing). No other new AM 510(k)s surfaced; DARPA and ARPA-H were quiet.

Clinical & research

• miRNA-programmed spheroids bioprint vascularized bone (Chemical Engineering Journal · via PubMed) — Penn State / Johns Hopkins report ~91% closure of critical-size skull defects in mice with vessel-like structures – a step toward vascularized bone grafts.
• 3D-bioprinted breast cancer-stroma model maps invasion (Advanced Healthcare Materials · via PubMed) — A Wurzburg team shows adipose-derived stromal cells drive tumor-cell migration – a more human-relevant model for cancer drug testing.
• Israel’s first full 3D-printed chest-cage reconstruction (VoxelMatters) — Clalit-Beilinson surgeons rebuilt a sarcoma patient’s sternum and ribs with a custom PEKK implant – patient-specific implants moving from novelty toward routine.

Also this week

• Bioprinted diaphragmatic-hernia patch (proof of concept) — France; myoblasts and fibroblasts bioprinted on a biodegradable albumin membrane, shielded by PLGA microscaffolds (Biofabrication, via PubMed).
• UNO wins $8M NSF award to launch the NE3D center — A statewide Nebraska hub for 3D-printed prosthetics and assistive devices, antimicrobial materials, and patient-specific solutions.
• TE Connectivity automates catheter-shaft jacketing — A new process 3D-prints jacketing directly onto catheter shafts (Galway), replacing a manual assembly step.
• ‘Little Wheels, Big Dreams’: a maker prints mobility trainers — MD+DI profiles Anthony Duran, who prints kid-friendly mobility trainers (~$265 in parts) and donates them where insurance won’t.
• PharmaTher tests GMP peptide 3D printing — With Craft Health’s room-temperature CraftMake platform, aimed at 503A compounding pharmacies for personalized peptide doses.
• KIST prints texture-tuned food for dysphagia — A chlorella-and-starch food ink prints meals matched to a patient’s swallowing ability – 3D printing reaches clinical nutrition.
• A primer on food-grade 3D printing — Useful reference on why printed parts aren’t automatically food-safe – and how food-grade differs from biocompatible.
• Phase3D supports NASA metal-AM flight qualification — Off our usual beat, but the in-situ, ‘born-qualified’ QA idea echoes into how regulated medical AM proves quality.

From 3DHEALS

• Episode 122: New Approach Methodologies (NAMs) with Dr. Lowry Curley — Brain organoids and organ-on-a-chip vs. animal testing – and why the FDA’s 2025-26 guidance is shifting pharma’s posture.
• Webinar (Aug 20): New Approach Methodologies – From Theory to Validation — Andrew Lee (FluidForm Bio) and Graham Craig (VoxCell) on validating NAMs with biofabrication and microfluidics. Register to join.
• Episode 119: Where Is Dental 3D Printing? with Dr. Nabeel Cajee — 3DHEALS’ dental ambassador on digital workflows, same-day restorations, and the printed-ceramics-vs-zirconia materials gap.

Subscribe to The Lattice Brief

The post Lattice Brief: FDA Clears First 3D-Printed Implant Made at the Point of Care appeared first on 3DHeals.